Index of artpub/2022/289740/

Barr, Paul M
Many people with chronic lymphocytic leukemia or small lymphocytic lymphoma benefit from ibrutinib treatment up to 8 years : a plain language summary
2022
https://ddd.uab.cat/record/289740